Bristol-Myers Hit With False Marking Suit Over 3 Drugs
Frequent qui tam plaintiff Promote Innovation LLC has accused Bristol-Myers Squibb Co. of marking its antibiotic Cefzil, its anti-anxiety medication Buspar and its cholesterol drug Pravachol with expired or inapplicable patents....To view the full article, register now.
Already a subscriber? Click here to view full article